Abstract
Clinical lipidomics is an important merging discipline to integrate clinical medicine and lipid science for diagnosis and therapy of human disease. The clinical lipidomics is defined as a new integrative biomedicine to discover the correlation and regulation between a large scale of lipid elements measured and analyzed in liquid biopsies from patients with those patient phenomes and clinical phenotypes. One of the important and challenging issues in clinical lipidomics is to define the disease specificity of dyslipidemia and lipid dysregulation. The comparison of lipidomic profile difference between target disease and healthy as well as related diseases is a common approach to perform lipidomics in patients. It is challenging to define the disease specificity of lipids and lipid metabolism, especially for those lipid species and their abundances. The heterogeneity of lipidomic profiles between different diseases is more obvious than that between different stages or severities of one disease. It is a challenge to validate the stage or severity specificity of selected biomarkers and targets. In order to improve the understanding of disease mechanisms in multiple dimensions, clinical lipidomics should/must be merged with clinical phenomes, e.g. patient signs and symptoms, biomedical analyses, pathology, images, and responses to therapies. We believe clinical lipidomics will become one of the most important and helpful approaches during the design and decision-making of therapeutic strategies for individuals.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aidoud N, Delplanque B, Baudry C, Garcia C, Moyon A, Balasse L, et al. A combination of lipidomics, MS imaging, and PET scan imaging reveals differences in cerebral activity in rat pups according to the lipid quality of infant formulas. FASEB J. 2018:fj201800034R. https://doi.org/10.1096/fj.201800034R.
Chen H, Song ZJ, Qian MJ, Bai CX, Wang XD. Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: a preliminary study. J Cell Mol Med. 2012a;16(6):1286–97.
Chen H, Wang YL, Bai CX, Wang XD. Alterations of serum inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. J Cell Mol Med. 2012b;16(6):1286–97.
Chen C, Shi L, Li Y, Wang X, Yang S. Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia. Cell Biol Toxicol. 2016;32(3):169–84. https://doi.org/10.1007/s10565-016-9322-4.
Gorden DL, Myers DS, Ivanova PT, Fahy E, Maurya MR, Gupta S, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res. 2015;56(3):722–36. https://doi.org/10.1194/jlr.P056002.
Kim WS, Jary E, Pickford R, He Y, Ahmed RM, Piguet O, et al. Lipidomics analysis of behavioral variant frontotemporal dementia: a scope for biomarker development. Front Neurol. 2018;9:104. https://doi.org/10.3389/fneur.2018.00104. eCollection 2018
Lv J, Gao D, Zhang Y, Wu D, Shen L, Wang X. Variations of lipidomic profiles among lung cancer subtypes of patients. J Cell Mol Med. 2018; accepted.
Lydic TA, Goo YH. Lipidomics unveils the complexity of the lipidome in metabolic diseases. Clin Transl Med. 2018;7(1):4. https://doi.org/10.1186/s40169-018-0182-9.
Ščupáková K, Soons Z, Ertaylan G, Pierzchalski KA, Eijkel GB, Ellis SR, et al. Spatial systems lipidomics reveals nonalcoholic fatty liver disease heterogeneity. Anal Chem. 2018. https://doi.org/10.1021/acs.analchem.7b05215.
Shi L, Zhu B, Xu M, Wang X. Selection of AECOPD-specific immunomodulatory biomarkers by integrating genomics and proteomics with clinical informatics. Cell Biol Toxicol. 2018a;34(2):109–23. https://doi.org/10.1007/s10565-017-9405-x. Epub 2017 Aug 4
Shi L, Dong N, Ji D, Huang X, Ying Z, Wang X, Chen C. Lipopolysaccharide-induced CCN1 production enhances interleukin-6 secretion in bronchial epithelial cells. Cell Biol Toxicol. 2018b;34(1):39–49. https://doi.org/10.1007/s10565-017-9401-1.
Wang X. Clinical trans-omics: an integration of clinical phenomics with multiomics. Cell Biol Toxicol. 2018 Jun;34(3):163-166. https://doi.org/10.1007/s10565-018-9431-3
Xu M, Wang X. Critical roles of mucin-1 in sensitivity of lung cancer cells to tumor necrosis factor-alpha and dexamethasone. Cell Biol Toxicol. 2017;33(4):361–71. https://doi.org/10.1007/s10565-017-9393-x.
Zhu D, Liu Z, Pan Z, Qian M, Wang L, Zhu T, Xue Y, Wu D. A new method for classifying different phenotypes of kidney transplantation. Cell Biol Toxicol. 2016;32(4):323–32. https://doi.org/10.1007/s10565-016-9337-x.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Wang, X. (2018). Clinical Lipidomics: A Critical Approach for Disease Diagnosis and Therapy. In: Wang, X., Wu, D., Shen, H. (eds) Lipidomics in Health & Disease. Translational Bioinformatics, vol 14. Springer, Singapore. https://doi.org/10.1007/978-981-13-0620-4_1
Download citation
DOI: https://doi.org/10.1007/978-981-13-0620-4_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-0619-8
Online ISBN: 978-981-13-0620-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)